Wisp Review

Wisp's verdict: a brand-name menu with one honest experiment attached

Wisp (hellowisp.com) is one of the few telehealth companies that will sell you an FDA-approved injectable and, on the very same weight-care page, tell you in plain language that its own signature compounded product hasn't been tested in a human body. That candor is the most useful thing about this provider. If you want real GLP-1 medication with a clear paper trail, Wisp can route you to branded semaglutide (Wegovy) and tirzepatide-based Zepbound, with Saxenda as a third option. If you're shopping specifically for the cheap, needle-free sublingual drops it advertises, read the caveats before you get attached to the idea.

What you actually get for the money

The headline weight-care product is a compounded sublingual semaglutide drops formulation (a 15mL bottle) at $225 a month. That price includes the medication and free, discreet delivery to your door — there's no separate shipping charge layered on top. For context, the category median across providers we track sits around $170 a month, so Wisp's drops land on the higher side of compounded pricing despite being a less-proven format.

Wisp does not run a first-month teaser rate on the drops — the price you see is the price you pay from month one, which is at least refreshingly free of bait-and-switch promo math. A few adjacent products carry their own separate fees you should budget for: a weight-care consult priced in the high two figures per month, an optional metabolic-support and 'GLP-1 boost' capsule supplement starting in the mid-two-figures monthly (this is a supplement, not a prescription GLP-1 — don't confuse the two), and a metformin-for-PCOS option in the low-two-figure range.

The medications, and how they're dispensed

Wisp's weight vertical is broader than most compounded-only shops. The /shop/weight-care page lists branded Wegovy, Zepbound, and Saxenda — actual FDA-approved injectables — alongside the compounded sublingual drops. Wisp has also recently added 'Oral Wegovy' to the menu, though it doesn't publish a price for it, so you'd need to start an intake to learn the cost. The branded injectables are likewise listed without public prices, which is a real friction point: you can't comparison-shop the brand options up front.

Intake is asynchronous. A board-certified provider reviews your case and gets back to you within 24 to 72 hours, then the lowest starting dose is added to your cart and the clinician follows up with a plan tailored to you. Two named clinicians appear on the record — Dr. Shannon Chatham (DO) and Andrea Sleeth (WHNP-BC) — which is more transparency on the medical side than many competitors offer.

The sublingual drops: Wisp's differentiator, and its biggest asterisk

This is where Wisp earns both credit and caution. The drops are the product it's clearly betting on, and the company is unusually straight about their limits. Wisp's own product page states, verbatim, that while lab tests using human-derived tissues suggest the formulation may begin working within 15 to 30 minutes, 'it has not yet been tested within the human body,' that 'because of this, the effectiveness of this formulation in patients may vary,' and that compounded drugs 'are not FDA approved and do not undergo FDA safety, efficacy, or quality review.'

That is materially more cautious labeling than the compounded telehealth segment usually bothers with. The flip side is just as important: the entire efficacy case for GLP-1 weight loss — the trial data showing real, sustained results — comes from the injectables, not from sublingual drops. So you're paying a mid-range monthly rate for a delivery format with no human bioavailability data behind it. The saving grace is that if the drops underwhelm you, Wisp can pivot you to a branded injectable without changing providers.

• Best case: you want a needle-free entry point, you understand it's experimental, and you like having branded injectables one message away.
• Worst case: you assume sublingual drops work as well as a Wegovy shot — they have not been shown to, by Wisp's own admission.

Trust, safety, and oversight

Wisp is LegitScript certified, confirmed in the site footer — a meaningful baseline signal that the pharmacy operation passed a third-party legitimacy review. There's no FDA warning letter on file for Wisp; it did not appear in the large September 2025 sweep of 50-plus companies or the February 2026 telehealth sweep, and we found no litigation against it. Combined with the two named, credentialed clinicians and the unusually honest product copy, the oversight picture is solid for a compounding-adjacent telehealth brand.

The gaps are in disclosure, not safety. Wisp does not name its compounding pharmacy partners, and it does not publish the list of states it serves — so you'll have to confirm during intake that it operates where you live. Those omissions are why this provider sits at a measured confidence level in our scoring methodology rather than at the top.

Who should choose Wisp, and who should skip it

• Choose it if: you want access to branded Wegovy, Zepbound, or Saxenda from a LegitScript-certified provider with named clinicians, and you value a company that tells you the truth about what's unproven.
• Choose it if: you're curious about a sublingual alternative and you're going in with clear eyes about its experimental status.
• Skip it if: the sublingual drops are your main draw and you expected injectable-level results — the data isn't there.
• Skip it if: you need up-front pricing on the branded injectables before you'll commit, or you require a published list of covered states.

Bottom line

Wisp is a genuinely honest operator in a segment that often isn't. Its real strength is the combination of FDA-approved injectables, a LegitScript certification, named providers, and product copy that refuses to oversell. Its compounded sublingual drops at $225 a month are the hook, but they're also the weakest part of the value proposition — an unproven format at a not-cheap price. The smart way to use Wisp is to treat the drops as optional and the branded-injectable pathway as the main event. Just be ready to start an intake to see brand pricing, and to confirm your state is covered before you count on it.

For a side-by-side, Enhance MD ($212/month) and bmiMD ($99/month) are the most comparable options to weigh against Wisp.